Leerink Partnrs Forecasts Higher Earnings for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Equities researchers at Leerink Partnrs raised their Q4 2025 earnings per share estimates for Exact Sciences in a note issued to investors on Friday, May 2nd. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $0.26 per share for the quarter, up from their previous forecast of $0.18. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $706.79 million during the quarter, compared to the consensus estimate of $688.58 million. During the same quarter last year, the firm posted ($0.60) EPS. The company's quarterly revenue was up 10.9% on a year-over-year basis.

Several other equities research analysts also recently issued reports on EXAS. Barclays raised their price objective on shares of Exact Sciences from $55.00 to $75.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. Benchmark reissued a "buy" rating and set a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Evercore ISI boosted their price target on Exact Sciences from $60.00 to $66.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Mizuho began coverage on Exact Sciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $60.00 price objective on the stock. Finally, Piper Sandler decreased their price target on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $70.90.

Exact Sciences Stock Performance

Shares of NASDAQ EXAS traded down $1.18 during mid-day trading on Monday, reaching $51.88. 697,776 shares of the company were exchanged, compared to its average volume of 2,640,991. Exact Sciences has a twelve month low of $39.97 and a twelve month high of $72.83. The stock has a market capitalization of $9.79 billion, a P/E ratio of -9.31 and a beta of 0.92. The company's 50-day simple moving average is $45.47 and its 200-day simple moving average is $52.96. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97.

Hedge Funds Weigh In On Exact Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tidal Investments LLC boosted its stake in shares of Exact Sciences by 172.2% during the third quarter. Tidal Investments LLC now owns 34,275 shares of the medical research company's stock valued at $2,335,000 after purchasing an additional 21,683 shares in the last quarter. Synovus Financial Corp bought a new position in shares of Exact Sciences during the third quarter worth about $490,000. GAMMA Investing LLC increased its position in Exact Sciences by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,674 shares of the medical research company's stock valued at $206,000 after purchasing an additional 828 shares during the period. Everence Capital Management Inc. acquired a new stake in shares of Exact Sciences during the fourth quarter worth $356,000. Finally, Diversified Trust Co raised its stake in Exact Sciences by 5.9% during the fourth quarter. Diversified Trust Co now owns 12,639 shares of the medical research company's stock worth $710,000 after buying an additional 708 shares during the last quarter. Institutional investors own 88.82% of the company's stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.